Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster
The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages, including the BA.2-derived BA.2.75.2 and the BA.5-derived BQ.1.1 and XBB.1, have accumulated additional spike mutations that may affect vaccine effectiveness. Here we report neutralizing activities of...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 2023-02, Vol.29 (2), p.344-347 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 347 |
|---|---|
| container_issue | 2 |
| container_start_page | 344 |
| container_title | Nature medicine |
| container_volume | 29 |
| creator | Kurhade, Chaitanya Zou, Jing Xia, Hongjie Liu, Mingru Chang, Hope C. Ren, Ping Xie, Xuping Shi, Pei‑Yong |
| description | The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages, including the BA.2-derived BA.2.75.2 and the BA.5-derived BQ.1.1 and XBB.1, have accumulated additional spike mutations that may affect vaccine effectiveness. Here we report neutralizing activities of three human serum panels collected from individuals 23–94 days after dose 4 of a parental mRNA vaccine; 14–32 days after a BA.5 bivalent booster from individuals with 2–4 previous doses of parental mRNA vaccine; or 14–32 days after a BA.5 bivalent booster from individuals with previous SARS-CoV-2 infection and 2–4 doses of parental mRNA vaccine. The results showed that a BA.5 bivalent booster elicited a high neutralizing titer against BA.4/5 measured at 14–32 days after boost; however, the BA.5 bivalent booster did not produce robust neutralization against the newly emerged BA.2.75.2, BQ.1.1 or XBB.1. Previous infection substantially enhanced the magnitude and breadth of BA.5 bivalent booster-elicited neutralization. Our data support a vaccine update strategy that future boosters should match newly emerged circulating SARS-CoV-2 variants.
Circulating variants of SARS-CoV-2 continue to evade neutralization by COVID-19 vaccines, including bivalent boosters that target the BA.4/BA.5 variants of concern, suggesting that strategies to get ahead of the virus’ evolution might be warranted. |
| doi_str_mv | 10.1038/s41591-022-02162-x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2760816916</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2760816916</sourcerecordid><originalsourceid>FETCH-LOGICAL-c485t-d7a709188afc3c7fab7f3923527f9684793b9e49c0be80e52b2f012cc0f705823</originalsourceid><addsrcrecordid>eNp9kcFvFCEUxomxsbX6D3gwJF48yPiAYYDj7kZrk42NrZreCMOCmWZmWGGmbv3ry7pVEw8eCC-83_c98j6EXlCoKHD1NtdUaEqAsXJow8juETqhom4IlXD9uNQgFVFaNMfoac43AMBB6CfomDe15ALgBO3W8Qce_Twl23c_7dTFEceArxaXV2QVvxKGL4bOpfK6XFSskqJib_DyU0Uriu24wdfLZanaO7y1yY-T7fFw-XGBb61z3ehxTNjulQK33a3tC4HbGPPk0zN0FGyf_fOH-xR9ef_u8-oDWV-cna8Wa-JqJSaykVaCpkrZ4LiTwbYycM24YDLoRtVS81b7WjtovQIvWMsCUOYcBAlCMX6KXh98tyl-n32ezNBl5_vejj7O2TDZgKKNpk1BX_2D3sQ5jeV3hZKKcin1nmIHqmwl5-SD2aZusOnOUDD7XMwhF1NyMb9yMbsievlgPbeD3_yR_A6iAPwA5NIav_n0d_Z_bO8BEBiTZg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2778137796</pqid></control><display><type>article</type><title>Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Kurhade, Chaitanya ; Zou, Jing ; Xia, Hongjie ; Liu, Mingru ; Chang, Hope C. ; Ren, Ping ; Xie, Xuping ; Shi, Pei‑Yong</creator><creatorcontrib>Kurhade, Chaitanya ; Zou, Jing ; Xia, Hongjie ; Liu, Mingru ; Chang, Hope C. ; Ren, Ping ; Xie, Xuping ; Shi, Pei‑Yong</creatorcontrib><description>The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages, including the BA.2-derived BA.2.75.2 and the BA.5-derived BQ.1.1 and XBB.1, have accumulated additional spike mutations that may affect vaccine effectiveness. Here we report neutralizing activities of three human serum panels collected from individuals 23–94 days after dose 4 of a parental mRNA vaccine; 14–32 days after a BA.5 bivalent booster from individuals with 2–4 previous doses of parental mRNA vaccine; or 14–32 days after a BA.5 bivalent booster from individuals with previous SARS-CoV-2 infection and 2–4 doses of parental mRNA vaccine. The results showed that a BA.5 bivalent booster elicited a high neutralizing titer against BA.4/5 measured at 14–32 days after boost; however, the BA.5 bivalent booster did not produce robust neutralization against the newly emerged BA.2.75.2, BQ.1.1 or XBB.1. Previous infection substantially enhanced the magnitude and breadth of BA.5 bivalent booster-elicited neutralization. Our data support a vaccine update strategy that future boosters should match newly emerged circulating SARS-CoV-2 variants.
Circulating variants of SARS-CoV-2 continue to evade neutralization by COVID-19 vaccines, including bivalent boosters that target the BA.4/BA.5 variants of concern, suggesting that strategies to get ahead of the virus’ evolution might be warranted.</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/s41591-022-02162-x</identifier><identifier>PMID: 36473500</identifier><language>eng</language><publisher>New York: Nature Publishing Group US</publisher><subject>631/326/590/2293 ; 631/326/596/4130 ; Antibodies, Neutralizing ; Antibodies, Viral ; Biomedical and Life Sciences ; Biomedicine ; Brief Communication ; Cancer Research ; Coronaviruses ; COVID-19 ; COVID-19 vaccines ; Humans ; Infectious Diseases ; Metabolic Diseases ; Molecular Medicine ; mRNA ; mRNA Vaccines ; Mutation ; Neurosciences ; Neutralization ; Neutralizing ; Respiratory diseases ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Vaccine efficacy ; Vaccines ; Vaccines, Synthetic ; Viral diseases</subject><ispartof>Nature medicine, 2023-02, Vol.29 (2), p.344-347</ispartof><rights>The Author(s), under exclusive licence to Springer Nature America, Inc. 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2022. The Author(s), under exclusive licence to Springer Nature America, Inc.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c485t-d7a709188afc3c7fab7f3923527f9684793b9e49c0be80e52b2f012cc0f705823</citedby><cites>FETCH-LOGICAL-c485t-d7a709188afc3c7fab7f3923527f9684793b9e49c0be80e52b2f012cc0f705823</cites><orcidid>0000-0002-4022-6667 ; 0000-0001-5553-1616 ; 0000-0002-2520-7038 ; 0000-0003-0918-016X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41591-022-02162-x$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41591-022-02162-x$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36473500$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kurhade, Chaitanya</creatorcontrib><creatorcontrib>Zou, Jing</creatorcontrib><creatorcontrib>Xia, Hongjie</creatorcontrib><creatorcontrib>Liu, Mingru</creatorcontrib><creatorcontrib>Chang, Hope C.</creatorcontrib><creatorcontrib>Ren, Ping</creatorcontrib><creatorcontrib>Xie, Xuping</creatorcontrib><creatorcontrib>Shi, Pei‑Yong</creatorcontrib><title>Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages, including the BA.2-derived BA.2.75.2 and the BA.5-derived BQ.1.1 and XBB.1, have accumulated additional spike mutations that may affect vaccine effectiveness. Here we report neutralizing activities of three human serum panels collected from individuals 23–94 days after dose 4 of a parental mRNA vaccine; 14–32 days after a BA.5 bivalent booster from individuals with 2–4 previous doses of parental mRNA vaccine; or 14–32 days after a BA.5 bivalent booster from individuals with previous SARS-CoV-2 infection and 2–4 doses of parental mRNA vaccine. The results showed that a BA.5 bivalent booster elicited a high neutralizing titer against BA.4/5 measured at 14–32 days after boost; however, the BA.5 bivalent booster did not produce robust neutralization against the newly emerged BA.2.75.2, BQ.1.1 or XBB.1. Previous infection substantially enhanced the magnitude and breadth of BA.5 bivalent booster-elicited neutralization. Our data support a vaccine update strategy that future boosters should match newly emerged circulating SARS-CoV-2 variants.
Circulating variants of SARS-CoV-2 continue to evade neutralization by COVID-19 vaccines, including bivalent boosters that target the BA.4/BA.5 variants of concern, suggesting that strategies to get ahead of the virus’ evolution might be warranted.</description><subject>631/326/590/2293</subject><subject>631/326/596/4130</subject><subject>Antibodies, Neutralizing</subject><subject>Antibodies, Viral</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Brief Communication</subject><subject>Cancer Research</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 vaccines</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Metabolic Diseases</subject><subject>Molecular Medicine</subject><subject>mRNA</subject><subject>mRNA Vaccines</subject><subject>Mutation</subject><subject>Neurosciences</subject><subject>Neutralization</subject><subject>Neutralizing</subject><subject>Respiratory diseases</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Vaccine efficacy</subject><subject>Vaccines</subject><subject>Vaccines, Synthetic</subject><subject>Viral diseases</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>BENPR</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kcFvFCEUxomxsbX6D3gwJF48yPiAYYDj7kZrk42NrZreCMOCmWZmWGGmbv3ry7pVEw8eCC-83_c98j6EXlCoKHD1NtdUaEqAsXJow8juETqhom4IlXD9uNQgFVFaNMfoac43AMBB6CfomDe15ALgBO3W8Qce_Twl23c_7dTFEceArxaXV2QVvxKGL4bOpfK6XFSskqJib_DyU0Uriu24wdfLZanaO7y1yY-T7fFw-XGBb61z3ehxTNjulQK33a3tC4HbGPPk0zN0FGyf_fOH-xR9ef_u8-oDWV-cna8Wa-JqJSaykVaCpkrZ4LiTwbYycM24YDLoRtVS81b7WjtovQIvWMsCUOYcBAlCMX6KXh98tyl-n32ezNBl5_vejj7O2TDZgKKNpk1BX_2D3sQ5jeV3hZKKcin1nmIHqmwl5-SD2aZusOnOUDD7XMwhF1NyMb9yMbsievlgPbeD3_yR_A6iAPwA5NIav_n0d_Z_bO8BEBiTZg</recordid><startdate>20230201</startdate><enddate>20230201</enddate><creator>Kurhade, Chaitanya</creator><creator>Zou, Jing</creator><creator>Xia, Hongjie</creator><creator>Liu, Mingru</creator><creator>Chang, Hope C.</creator><creator>Ren, Ping</creator><creator>Xie, Xuping</creator><creator>Shi, Pei‑Yong</creator><general>Nature Publishing Group US</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-4022-6667</orcidid><orcidid>https://orcid.org/0000-0001-5553-1616</orcidid><orcidid>https://orcid.org/0000-0002-2520-7038</orcidid><orcidid>https://orcid.org/0000-0003-0918-016X</orcidid></search><sort><creationdate>20230201</creationdate><title>Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster</title><author>Kurhade, Chaitanya ; Zou, Jing ; Xia, Hongjie ; Liu, Mingru ; Chang, Hope C. ; Ren, Ping ; Xie, Xuping ; Shi, Pei‑Yong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c485t-d7a709188afc3c7fab7f3923527f9684793b9e49c0be80e52b2f012cc0f705823</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>631/326/590/2293</topic><topic>631/326/596/4130</topic><topic>Antibodies, Neutralizing</topic><topic>Antibodies, Viral</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Brief Communication</topic><topic>Cancer Research</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 vaccines</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Metabolic Diseases</topic><topic>Molecular Medicine</topic><topic>mRNA</topic><topic>mRNA Vaccines</topic><topic>Mutation</topic><topic>Neurosciences</topic><topic>Neutralization</topic><topic>Neutralizing</topic><topic>Respiratory diseases</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Vaccine efficacy</topic><topic>Vaccines</topic><topic>Vaccines, Synthetic</topic><topic>Viral diseases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kurhade, Chaitanya</creatorcontrib><creatorcontrib>Zou, Jing</creatorcontrib><creatorcontrib>Xia, Hongjie</creatorcontrib><creatorcontrib>Liu, Mingru</creatorcontrib><creatorcontrib>Chang, Hope C.</creatorcontrib><creatorcontrib>Ren, Ping</creatorcontrib><creatorcontrib>Xie, Xuping</creatorcontrib><creatorcontrib>Shi, Pei‑Yong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kurhade, Chaitanya</au><au>Zou, Jing</au><au>Xia, Hongjie</au><au>Liu, Mingru</au><au>Chang, Hope C.</au><au>Ren, Ping</au><au>Xie, Xuping</au><au>Shi, Pei‑Yong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2023-02-01</date><risdate>2023</risdate><volume>29</volume><issue>2</issue><spage>344</spage><epage>347</epage><pages>344-347</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>The newly emerged severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineages, including the BA.2-derived BA.2.75.2 and the BA.5-derived BQ.1.1 and XBB.1, have accumulated additional spike mutations that may affect vaccine effectiveness. Here we report neutralizing activities of three human serum panels collected from individuals 23–94 days after dose 4 of a parental mRNA vaccine; 14–32 days after a BA.5 bivalent booster from individuals with 2–4 previous doses of parental mRNA vaccine; or 14–32 days after a BA.5 bivalent booster from individuals with previous SARS-CoV-2 infection and 2–4 doses of parental mRNA vaccine. The results showed that a BA.5 bivalent booster elicited a high neutralizing titer against BA.4/5 measured at 14–32 days after boost; however, the BA.5 bivalent booster did not produce robust neutralization against the newly emerged BA.2.75.2, BQ.1.1 or XBB.1. Previous infection substantially enhanced the magnitude and breadth of BA.5 bivalent booster-elicited neutralization. Our data support a vaccine update strategy that future boosters should match newly emerged circulating SARS-CoV-2 variants.
Circulating variants of SARS-CoV-2 continue to evade neutralization by COVID-19 vaccines, including bivalent boosters that target the BA.4/BA.5 variants of concern, suggesting that strategies to get ahead of the virus’ evolution might be warranted.</abstract><cop>New York</cop><pub>Nature Publishing Group US</pub><pmid>36473500</pmid><doi>10.1038/s41591-022-02162-x</doi><tpages>4</tpages><orcidid>https://orcid.org/0000-0002-4022-6667</orcidid><orcidid>https://orcid.org/0000-0001-5553-1616</orcidid><orcidid>https://orcid.org/0000-0002-2520-7038</orcidid><orcidid>https://orcid.org/0000-0003-0918-016X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 2023-02, Vol.29 (2), p.344-347 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2760816916 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | 631/326/590/2293 631/326/596/4130 Antibodies, Neutralizing Antibodies, Viral Biomedical and Life Sciences Biomedicine Brief Communication Cancer Research Coronaviruses COVID-19 COVID-19 vaccines Humans Infectious Diseases Metabolic Diseases Molecular Medicine mRNA mRNA Vaccines Mutation Neurosciences Neutralization Neutralizing Respiratory diseases SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Vaccine efficacy Vaccines Vaccines, Synthetic Viral diseases |
| title | Low neutralization of SARS-CoV-2 Omicron BA.2.75.2, BQ.1.1 and XBB.1 by parental mRNA vaccine or a BA.5 bivalent booster |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T08%3A04%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Low%20neutralization%20of%20SARS-CoV-2%20Omicron%20BA.2.75.2,%20BQ.1.1%20and%20XBB.1%20by%20parental%20mRNA%20vaccine%20or%20a%20BA.5%20bivalent%20booster&rft.jtitle=Nature%20medicine&rft.au=Kurhade,%20Chaitanya&rft.date=2023-02-01&rft.volume=29&rft.issue=2&rft.spage=344&rft.epage=347&rft.pages=344-347&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/s41591-022-02162-x&rft_dat=%3Cproquest_cross%3E2760816916%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2778137796&rft_id=info:pmid/36473500&rfr_iscdi=true |